05 Mar

James Ivory Just Became The Oldest Person To Ever Win An Oscar

The Call Me by Your Name screenwriter is 89.

When 89-year-old Call Me by Your Name screenwriter James Ivory won the Academy Award for Best Adapted Screenplay on Sunday night, he became the oldest Oscar winner of all time.

When 89-year-old Call Me by Your Name screenwriter James Ivory won the Academy Award for Best Adapted Screenplay on Sunday night, he became the oldest Oscar winner of all time.

Frazer Harrison / Getty Images

Before the Oscars, Ivory’s script had already earned him the Writers Guild Award, the BAFTA, and the Critics’ Choice Award.

Before the Oscars, Ivory's script had already earned him the Writers Guild Award, the BAFTA, and the Critics' Choice Award.

Sony Pictures Classics

Ivory has had a long and celebrated career. With his late partner Ismail Merchant, he founded Merchant Ivory productions, whose films include A Room With a View, Howards End, and the 1987 gay romance Maurice.

Ivory has had a long and celebrated career. With his late partner Ismail Merchant, he founded Merchant Ivory productions, whose films include A Room With a View, Howards End, and the 1987 gay romance Maurice.

Merchant Ivory

The previous oldest winner of all time, Christopher Plummer, was 82 when he won Best Supporting Actor for Beginners. He remains the oldest acting Oscar winner.

The previous oldest winner of all time, Christopher Plummer, was 82 when he won Best Supporting Actor for Beginners. He remains the oldest acting Oscar winner.

He was nominated tonight for Best Supporting Actor in All the Money in the World. At 88, he’s also the oldest acting Oscar nominee – and if he’d won, he would have broken his own record for oldest acting winner.

Focus Features

It’s worth noting that Best Documentary Feature nominee Agnès Varda would have been the oldest winner if she’d won for Faces Places. She is EIGHT DAYS OLDER than Ivory.

It's worth noting that Best Documentary Feature nominee Agnès Varda would have been the oldest winner if she'd won for Faces Places. She is EIGHT DAYS OLDER than Ivory.

She has also received an Academy Honorary Award for her contributions to cinema.

AFP / Getty Images

Congratulations to this new record holder!

Congratulations to this new record holder!

ABC

02 Mar

Bio Roundup: Funding Frenzy, Opioid Summit, Celgene Woes & More

Biotech startups rolled in cash this week. By our count, investors put more than $800 million into life-sciences startups in four days. The money came from a wide range of backers, not just traditional biotech venture firms. It’s early yet in 2018, but the current count could put life-sciences companies on pace to bust past last year’s $17.6 billion, a figure compiled in the Venture Monitor Report.

Elsewhere, the U.S. Justice Department unveiled a new task force that will go after the makers and distributors of opioid drugs, Celgene shocked investors with an unexpected setback, and a planned $4.3 billion merger… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

02 Mar

Development and long-term sustainability of new pan-European research infrastructures

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-INFRADEV-2018-2020Pillar: Excellent ScienceOpening Date: Deadline: Thu, 22 Mar 2018 17:00:00 (Brussels local time)Modification Date: Fri, 2 Mar 2018Latest information: We herewith bring to the attention of applicants that they are permitted to remove the page break on the cover page of the technical annex’s template. This means that the text of the proposal can start on the cover page.

02 Mar

Reps. Upton and Dingell on Solving America’s Opioid Crisis

Writing this morning for the Detroit Free Press, Reps. Fred Upton (R-MI) and Debbie Dingell (D-MI) reinforce the need for innovation to help combat opioid abuse and addiction in America. As they state:

“While it’s true there is no magic-wand to address this issue, we must recognize that if we’re going to achieve an addiction free nation, it will depend on smart science and a regulatory environment that promotes pain management alternatives.”

Achieving an addiction free America will not happen overnight. In fact, as a nation we’re spending more than $500 billion annually in health and social costs to combat this epidemic. But as Reps. Upton and Dingell explain, smart science and a regulatory environment that promotes pain management alternatives can help get our nation back on track.

“We can innovate our way out of the opioid crisis, but to do so we must face the challenges that stand in our way. It’s essential that we speed the commercialization of new, non-addictive painkillers – and ensure that neuroscience breakthroughs to treat opioid addiction are more accessible to patients.”

Consistent with the recommendations BIO recently released, Reps. Upton and Dingell agree that access to novel, safer treatments needs to be a top priority if we’re going to end this public health crisis. And as we’ve pointed out before, this can be achieved by breaking the barriers that impede patients’ access to the most appropriate treatments – including medication assisted treatment – and stimulating the development of novel and safer therapies to manage this growing public health crisis.

To read the full op-ed in the Detroit Free Press, click here. For more on BIO’s commitment to developing solutions that will allow for an addiction free America, click here.

 

 

 

 

01 Mar

Nkarta Therapeutics Picks Paul Hastings for CEO

Paul Hastings has been named CEO of South San Francisco, CA-based Nkarta Therapeutics. Hastings most recently worked for Redwood City, CA, cancer drug developer OncoMed Pharmaceuticals (NASDAQ: OMED), where he was chairman and CEO. Hastings resigned from OncoMed on Jan. 1. Nkarta is developing cancer treatments based on natural killer (NK) immune cells.

UNDERWRITERS AND PARTNERS

          

          

            

01 Mar

2018-2020 Digitising and Transforming European Industry and Services: Automated Road Transport

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-DT-ART-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Thu, 23 Apr 2020 17:00:00 (Brussels local time)Modification Date: Thu, 1 Mar 2018Latest information: IMPORTANT – Page limits applicable to proposals:
Applicants are allowed to remove the page break in the cover page of the template for the technical annex, i.e. the proposal text can start on the cover page.

01 Mar

Bill Gates Calls GMOs ‘Perfectly Healthy’ – And Scientists Say He’s Right

Bill Gates has a message for those advocating against genetically modified organisms: I’m disappointed.

Business Insider science correspondent Erin Brodwin explains:

In a Reddit “Ask Me Anything” post on Tuesday, Gates said that not only does he view genetically modified foods as “perfectly healthy,” but that he sees them as a promising tool in a wider array of resources in the fight to reduce world hunger.

“GMO foods are perfectly healthy and the technique has the possibility to reduce starvation and malnutrition when it is reviewed in the right way,” Gates wrote. “I don’t stay away from non-GMO foods but it is disappointing that people view it as better.”

Gates’ view may strike some as controversial, as many people think that genetically modified foods are dangerous.

In recent years, companies have submitted more than 43,000 products to the Non-GMO Project, an organization that certifies products that don’t contain genetically modified ingredients. And sales of such products are skyrocketing – today, they represent more than $22 billion in yearly sales, the organization says.

But Gates’ stance is in line with that of most scientists who study the topic.

Organizations like the National Academy of Sciences, the American Association for the Advancement of Science, and the European Commission have publicly said genetically modified foods are safe to eat. A large 2013 study on GMOs found no “significant hazards directly connected with the use of genetically engineered crops.”

And nearly all the food we eat today has been genetically modified in some way. Dozens of crops, from corn to watermelon, have been selectively bred for thousands of years to give us the traits we find desirable, like large amounts of sweet, edible flesh, or small seeds.

And many other products – some of them life-saving – might not exist without genetically modified ingredients.

Insulin, the medication that people with diabetes depend on to regulate their blood sugar, is made with such ingredients, while the cotton used to make the shirt you’re wearing was most likely genetically modified.

Several experts say the “GMO” label does a disservice to the products made with genetically modified ingredients. The process of genetic modification is a breeding method, much like other recent advances in agriculture.

“What are we labeling here, DNA?” Alison Van Eenennaam, a professor of animal genomics at the University of California at Davis, recently told Business Insider. “There’s DNA in everything, so good luck with that.”

01 Mar

Rubius Rolls Up Another $100M As Bio Funding Frenzy Continues

Like water spewing from a firehose, venture dollars are dousing life-science startups this week. The latest biotech on the receiving end is Rubius Therapeutics, a cell therapy developer that announced a $100 million round this morning.

With the new cash, a “crossover” round including investors that back both private and publicly traded companies, Rubius has now raised $220 million from founding backer Flagship Pioneering and others in nine months. Rubius president Torben Straight Nissen said the company is funded by institutional biotech investors and “some of the largest mutual funds in the world,” but wouldn’t provide specifics.

The cash and… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

01 Mar

We’re Reaching a Tipping Point in the Biobased Economy

In a piece for Biofuels Digest, BIO’s Executive Vice President, Industrial & Environmental Section, Brent Erickson (@BErickson_BIO) argues that the biobased economy is at a tipping point. With an estimated $355.28 billion in global economic value, Erickson dives into the biobased economy’s impact to date and the U.S. federal and state policies that must be addressed to keep up with the industry’s rapid growth.

Read the full piece below and be sure to check out Brent Erickson’s presentation on the biobased economy at Biofuels Digest’s Advanced Biofuels Leadership Conference on March 1, 2018 in Washington, D.C.

Also, don’t forget to register for BIO’s World Congress on Industrial Biotechnology in Philadelphia, July 16-19, 2018. BIO’s World Congress is the world’s largest conference on industrial biotechnology.

BIO is the only trade association that advocates for the diverse policies that support the entire biobased economy – the full value chain of technologies and infrastructure to convert renewable, low-carbon, low-cost feedstocks and waste streams into value-added consumer products, including renewable chemicals and biofuels.

The unifying factor among BIO’s members is their use of biotechnology in their drive to commercialize new, advanced and more sustainable technologies. That mission brings together researchers, producers and companies from across the entire biobased economy. And the value chain is constantly growing and changing, driven by the rapid pace of innovation in industrial biotechnology. It seems there are always new, innovative companies emerging to develop first-of-a-kind products, technologies and new feedstocks.

At the same time, after some fits and starts, the biobased economy is approaching a tipping point in its growth and maturation. Already, a number of companies have successfully commercialized technologies for renewable chemicals, built biorefineries and created supply chains – and turned their attention to commercializing their next product. The economic impact is evident. Bioeconomy Capital estimates that renewable chemicals now generate the equivalent of around one half of 1 percent (0.5%) of U.S. GDP, while petrochemicals generate around 3 percent. Put a different way, for every $7 contributed to the U.S. economy by the chemical industry, $1 is coming from renewable chemicals.

Several studies and market analyses have aimed to calculate the economic value of the entire biobased economy. However, no single study captures all of the economic impacts across the full value chain.

Bioeconomy Capital also estimates that the U.S. industrial biotechnology sector – which they define to include renewable chemicals, nutritional ingredients and biotech R&D industries, among others – generated more than $140 billion in business-to-business revenue in 2016. The sector experienced tremendous growth since 2012, when total revenue was $105 billion, according to their report.

A USDA study shows that direct revenue from renewable chemicals and biobased products (those eligible for the BioPreferred® program) grew to $127 billion, providing direct employment to 1.53 million U.S. workers. With a strong multiplier for job creation, the biobased product sector’s indirect economic impact reached $393 billion in 2014. The two studies cover some of the same industries, but not the entire biobased economy.

Looking at several studies that measure various elements of the value chain, BIO calculates that the global economic value of the biobased economy – including industrial biotechnology, renewable chemicals and polymers, biofuels, enzymes and biobased materials – is $355.28 billion. The United States generates 58 percent of the global value of biased manufacturing, or more than $205 billion. And that economic activity supports employment for 1.66 million U.S. workers.

As industry leaders, we need to help policy makers understand that the entire value chain creates economic opportunities – policy should include support at every stage to ensure that the biobased economy reaches critical mass. For instance, the U.S. tax code should recognize renewable chemicals to keep the United States competitive in commercializing this homegrown technology. A top priority for BIO is the Qualified Renewable Chemicals Tax Credit. We have been building congressional support for this critical legislation, which will provide renewable chemicals similar tax credits enjoyed by other alternative energies. Congress must recognize other countries are providing incentives for companies to build commercial production capacity – those countries will capture the jobs and the economic growth from the biobased economy, unless the United States levels the playing field.

BIO is leading the way to secure reauthorization of the Farm Bill energy title programs that will develop and incentivize investment in the biobased economy. Congress should consider changing the name of that title, because it is now broader than just energy. The Farm Bill energy title programs have supported the emergence of the biobased economy here in the United States and compiled a record of success that deserves to be continued.

Reauthorization of these programs will provide crucial access to capital and marketspace for companies developing renewable chemicals; those are key ingredients for building manufacturing infrastructure.

Industrial biotechnology will continue to drive growth in the biobased economy. It’s difficult to predict where innovation will take us. But the economic impact is becoming evident; the biobased economy is a measurable percentage of overall U.S. productivity. BIO is working to ensure U.S. federal and state policy keeps up with this growth.

28 Feb

Arcturus Fails to Ratify Auditor in Latest Fallout After CEO Firing

The schism between Arcturus Therapeutics’ board and its former chief executive is now putting the company at risk of missing key financial reporting deadlines, and possibly even losing its stock listing.

The San Diego drug developer said late Monday that the typically routine step of ratifying the company’s auditor failed a shareholder vote. Arcturus (NASDAQ: ARCT) blamed the failure on Joseph Payne, who was fired as CEO on Feb. 1. Though Payne no longer works for Arcturus, he still owns 13.7 percent of the company’s shares and sits on its board of directors.

Arcturus says Payne and others… Read more »

UNDERWRITERS AND PARTNERS